Communicating with Limited English Patients Via a Language Interpreter
Pharmacists are a vital part of patient health management. The role of the pharmacist has adapted and changed based on the needs of the communities they serve. A 2015 U.S. Census Bureau reports that there are at least 350 Languages used in U.S. homes, requiring pharmacists to be able to overcome language barriers to deliver patient-centered care. The current landscape suggests that pharmacists lack the knowledge of available resources and lack of confidence to incorporate these resources into their daily practice. By completing this continuing education training program, pharmacists should be able to provide better care to limited-English proficient (LEP) patients by incorporating best practices that are explained in depth. This can help improve quality of care, reduce the chance of medication errors, and contribute to improving health literacy. This training lends itself to the overall discussion of cultural competency and health literacy among LEP patients. This module also includes an opportunity to participate in a research survey - to learn more, pay close attention to the program description available when you log-in to our CE portal.
Upon completion of this activity, the participant should be able to:
- Identify how effective interpreter use in practice can impact patient care.
- Explain legal requirements for language and interpreter services and apply them to the clinical setting.
- Establish ‘best practices’ for communicating with patients via a language interpreter including setting ground rules, cultural awareness, and communication tips.
- Recognize the role of pharmacists in delivering culturally competent, linguistically appropriate patient care when utilizing interpreter services to communicate with ELP patients.
Patsy Casalino, PharmD
Patsy Casalino is a post-doctoral fellow at MCPHS University and Biogen. Patsy received his Doctor of Pharmacy from MCPHS University – Boston campus in 2018. At Biogen, Patsy is part of Regulatory Sciences/Safety and Benefit-Risk Management fellowship program which provides him with the opportunity to gain experience across a variety of therapeutic areas and functions. In addition, Patsy serves as an adjunct faculty member at MCPHS University where he participates in teaching activities and is the MCPHS Fellow’s Network (MFN) President for the 2019-2020 fellowship year.
Hannah Hoseyni, PharmD
Hannah Hoseyni is a post-doctoral fellow at MCPHS University and Biogen. Hannah received her Doctor of Pharmacy from University of Pittsburgh School of Pharmacy in 2019. Hannah is part of the Global Regulatory Sciences fellowship program, which provides the opportunity to gain experience working with US, Global early phase and Global late phase regulatory science teams across therapeutic areas. In addition, Hannah serves as an adjunct faculty member at MCPHS University where she will participate in teaching activities.
Lori Yeterian, PharmD, RPh
Lori Yeterian is a post-doctoral fellow at MCPHS University and Biogen. Lori received her Doctor of Pharmacy from MCPHS University – Boston campus in 2018. As a fellow at Biogen, Lori has worked in Regulatory, Medical Affairs, and Drug Safety. Lori has also served as a preceptor for pharmacy students completing their experiential rotations at Biogen.
Registration Fee: This module is provided free of charge.
Release Date: December 6, 2019
Expiration Date: December 6, 2022
Contact Hours: 1.0 (0.1 CEU)
ACPE UAN: 0026-0000-19-017-H05-P
ACPE Topic Designator: Patient Safety
Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this educational activity for a total of 1 contact hours (0.1 CEUs).
In order to receive credit, the participant must view the entire presentation and complete the pre and post-test, and evaluation. Upon completion participant credit will be reported to CPE Monitor. Transcripts may be printed from CPE Monitor.
It is the policy of Massachusetts College of Pharmacy and Health Sciences Continuing Education to ensure balance, independence, objectivity and scientific rigor in all of its educational activities. All individuals engaged in the planning of a continuing education activity and who are in a position to control the educational content are required to disclose any financial relationships with ineligible companies occurring within the past 24 months. The intent of this policy is to identify and mitigate any potential conflict of interest that may directly or indirectly affect the activity. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
MCPHS will identify, review and mitigate all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Patsy Casalino, Hannah Hoseyni, and Lori Yeterian have no relevant financial relationships with ineligible companies to disclose.
Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.
No funding from industry provided for this event. No exhibitors will be present.